Option chain shows key data for Bio-Path Hldgs's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Bio-Path Hldgs.

Bio-Path Hldgs (NASDAQ:BPTH) Stock, Option Chain

Bio-Path Hldgs

Bio-Path Holdings

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.

Wall Street US stocks

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

ALCE

BPTH

DOCU

Nasdaq Surges Over 1%; DocuSign Shares Spike Higher

Crude-oil-4-logo

SAVA

Crude Oil Falls Over 4%; US Trade Deficit Narrows In August

Wall-Street-dall

Earnings

NMHI

OCFT

US Stocks Edge Higher; PepsiCo Cuts 2024 Revenue Outlook

Bio-Path Holdings Inc

Bio-Path Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-15. Here's what investors need to know before the announcement.
Analysts estimate that Bio-Path Holdings will report an earnings per share (EPS) of $-1.02. 
Anticipation surrounds Bio-Path Holdings's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.38, leading to a 1.32% drop in the share price on the subsequent day.
Here's a look at Bio-Path Holdings's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.54</td>
<td>-4.80</td>
<td>-5.40</td>
<td>-6.8</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.16</td>
<td>-4.88</td>
<td>-4.23</td>
<td>-6.4</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-1.0%</td>
<td>-13.0%</td>
<td>-6.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731592867_0.png" alt="eps graph" />
<h3>Market Performance of Bio-Path Holdings's Stock</h3>
Shares of Bio-Path Holdings were trading at $0.884 as of November 13. Over the last 52-week period, shares are down 91.66%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/BPTH/earnings">To track all earnings releases for Bio-Path Holdings visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Uncovering Potential: Bio-Path Holdings's Earnings Preview

<h3>Gainers</h3>
<ul>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares increased by 51.2% to $0.51 during Wednesday's pre-market session. The market value of their outstanding shares is at $10.6 million. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) stock rose 23.64% to $1.83. The company's market cap stands at $136.7 million. </li>
<li>Kezar Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZR#NASDAQ">KZR</a>) stock moved upwards by 21.54% to $0.9. The company's market cap stands at $65.6 million. </li>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares increased by 18.47% to $1.09. The market value of their outstanding shares is at $1.7 million. </li>
<li>Aethlon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEMD#NASDAQ">AEMD</a>) stock increased by 10.83% to $0.44. The market value of their outstanding shares is at $6.1 million. </li>
<li>Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) stock rose 10.28% to $0.35. The market value of their outstanding shares is at $26.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) stock decreased by 11.8% to $0.6 during Wednesday's pre-market session. The market value of their outstanding shares is at $6.3 million. </li>
<li>Tivic Health Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) stock fell 11.53% to $0.23. The market value of their outstanding shares is at $1.4 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares decreased by 10.93% to $1.06. The market value of their outstanding shares is at $2.7 million. </li>
<li>Cue Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUE#NASDAQ">CUE</a>) shares declined by 9.44% to $1.11. The company's market cap stands at $67.0 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) stock decreased by 9.31% to $0.58. The market value of their outstanding shares is at $5.8 million. </li>
<li>Exicure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) stock decreased by 7.2% to $2.41. The company's market cap stands at $5.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AEMD

CLSD

CTCX

NIVF

TIVC

WINT

XCUR

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Reported Earlier, Bio-Path Holdings Raises $4M Through At-the-Market Private Placement

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 1% on Tuesday.
The Dow traded up 0.20% to 42,038.02 while the NASDAQ rose 1.15% to 18,130.89. The S&amp;P 500 also rose, gaining, 0.77% to 5,739.69.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41224334/top-2-energy-stocks-you-may-want-to-dump-in-q4">Top 2 Energy Stocks You May Want To Dump In Q4</a>
Leading and Lagging Sectors Information technology shares jumped by 1.6% on Tuesday.
In trading on Tuesday, energy shares dipped by 2.4%.
Top Headline
The trade deficit in the U.S. shrank to $70.4 billion in August, recording the lowest level in five months, compared to a revised $78.9 billion gap in July and versus market estimates of a $70.6 billion shortfall.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Alternus Clean Energy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALCE#NASDAQ">ALCE</a>) shares shot up 13% to $0.1690. Alternus shed $100 million of debt and payables, improved shareholder equity position by Circa $45 million from disposal of certain subsidiaries.</li>
<li>Shares of Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) got a boost, surging 18% to $1.0199. The company initiated a therapeutic program to develop BP1001-A for treating obesity and related metabolic diseases. This program marks the first application of DNAbilize technology to develop a non-cancer application.</li>
<li>DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) shares were also up, gaining 8% to $67.94 after it was announced the company will join the S&amp;P MidCap 400.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ZJK Industrial Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) shares dropped 27% to $4.97 after gaining 35% on Monday.</li>
<li>Shares of JinkoSolar Holding Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>) were down 19% to $26.54.</li>
<li>Lufax Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LU#NYSE">LU</a>) was down, falling 15% to $3.39. Shares of US-listed Chinese stocks traded lower after Chinese planning officials reportedly fell short of investor stimulus expectations.</li>
</ul>
Commodities In commodity news, oil traded down 3.8% to $74.20 while gold traded down 1.2% at $2,634.70.
Silver traded down 4.4% to $30.610 on Tuesday, while copper fell 2.4% to $4.4560.
Euro zone
European shares closed mostly lower today. The eurozone's STOXX 600 fell 0.55%, Germany's DAX fell 0.20% and France's CAC 40 fell 0.72%. Spain's IBEX 35 Index rose 0.15%, while London's FTSE 100 fell 1.36%.
France's trade deficit increased to €7.4 billion in August versus a revised €6.0 billion gap in the previous month. Germany's industrial production rose by 2.9% month-over-month in August, compared to a revised 2.9% fall in the previous month,
Asia Pacific Markets
Asian markets closed mostly lower on Tuesday, with Japan's Nikkei 225 falling 1%, Hong Kong's Hang Seng Index dipping 9.41%, China's Shanghai Composite Index falling 4.59% and India's BSE Sensex gaining 0.72%.
The gauge for Japan's service sector fell to 47.8 in September compared to 49.0 in the prior month. Japan's current account surplus widened to JPY 3,803.6 billion in August from JPY 2,293.8 billion in the year-ago month.
Economics
<ul>
<li>The NFIB Small Business Optimism Index rose to 91.5 in September compared to 91.2 in August, and down from market estimates of 91.7.</li>
<li>The trade deficit in the U.S. shrank to $70.4 billion in August, recording the lowest level in five months, compared to a revised $78.9 billion gap in July and versus market estimates of a $70.6 billion shortfall.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/10/41226784/how-to-earn-500-a-month-from-dominos-pizza-stock-ahead-of-q3-earnings-results"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41226784/how-to-earn-500-a-month-from-dominos-pizza-stock-ahead-of-q3-earnings-results">How To Earn $500 A Month From Domino&#8217;s Pizza Stock Ahead Of Q3 Earnings Results</a></li>
</ul>
<a href="https://www.benzinga.com/news/earnings/24/10/41226784/how-to-earn-500-a-month-from-dominos-pizza-stock-ahead-of-q3-earnings-results">&nbsp;</a>

<h3>Gainers</h3>
<ul>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares increased by 68.5% to $3.07 during Tuesday's regular session. The market value of their outstanding shares is at $9.8 million. </li>
<li>Regional Health Props (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/RHE#AMEX">RHE</a>) stock increased by 31.31% to $2.39. The company's market cap stands at $4.5 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares moved upwards by 26.86% to $1.08. The market value of their outstanding shares is at $2.7 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) shares moved upwards by 23.21% to $6.74. The company's market cap stands at $7.0 million. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares moved upwards by 18.18% to $5.2. The market value of their outstanding shares is at $67.6 million. </li>
<li>Shattuck Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STTK#NASDAQ">STTK</a>) stock rose 15.48% to $1.3. The market value of their outstanding shares is at $62.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock fell 29.1% to $0.5 during Tuesday's regular session. The market value of their outstanding shares is at $15.2 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares fell 18.6% to $0.44. The market value of their outstanding shares is at $7.5 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares decreased by 14.46% to $0.12. The market value of their outstanding shares is at $1.3 million. </li>
<li>Galecto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLTO#NASDAQ">GLTO</a>) shares declined by 14.36% to $7.25. The company's market cap stands at $9.0 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares declined by 14.22% to $0.34. The market value of their outstanding shares is at $24.4 million. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) shares decreased by 13.65% to $34.5. The company's market cap stands at $224.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

GLTO

LGMK

OTRK

PRTG

RNAZ

STTK

VINC

XAIR

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 200 points on Tuesday.
The Dow traded up 0.17% to 42,026.90 while the NASDAQ rose 1.15% to 18,130.79. The S&amp;P 500 also rose, gaining, 0.75% to 5,738.42.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41224334/top-2-energy-stocks-you-may-want-to-dump-in-q4">Top 2 Energy Stocks You May Want To Dump In Q4</a>
Leading and Lagging Sectors Information technology shares jumped by 1.4% on Tuesday.
In trading on Tuesday, energy shares dipped by 2.6%.
Top Headline
The trade deficit in the U.S. shrank to $70.4 billion in August, recording the lowest level in five months, compared to a revised $78.9 billion gap in July and versus market estimates of a $70.6 billion shortfall.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Alternus Clean Energy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALCE#NASDAQ">ALCE</a>) shares shot up 48% to $0.2218. Alternus shed $100 million of debt and payables, improved shareholder equity position by Circa $45 million from disposal of certain subsidiaries.</li>
<li>Shares of Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) got a boost, surging 36% to $1.18. The company initiated a therapeutic program to develop BP1001-A for treating obesity and related metabolic diseases. This program marks the first application of DNAbilize technology to develop a non-cancer application.</li>
<li>Cassava Sciences, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) shares were also up, gaining 21% to $30.64. Cassava announced separation of CEO and board roles. HC Wainwright &amp; Co. analyst Vernon Bernardino upgraded Cassava Sciences from Neutral to Buy and announced a $116 price target.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ZJK Industrial Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) shares dropped 29% to $4.8001 after gaining 35% on Monday.</li>
<li>Shares of JinkoSolar Holding Co., Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>) were down 20% to $26.32.</li>
<li>Lufax Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LU#NYSE">LU</a>) was down, falling 15% to $3.3550. Shares of US-listed Chinese stocks traded lower after Chinese planning officials reportedly fell short of investor stimulus expectations.</li>
</ul>
Commodities In commodity news, oil traded down 4.4% to $73.72 while gold traded down 0.3% at $2,657.00.
Silver traded down 2.2% to $31.310 on Tuesday, while copper fell 1.8% to $4.4845.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.43%, Germany's DAX fell 0.08% and France's CAC 40 fell 0.70%. Spain's IBEX 35 Index slipped 0.06%, while London's FTSE 100 fell 1.21%.
France's trade deficit increased to €7.4 billion in August versus a revised €6.0 billion gap in the previous month. Germany's industrial production rose by 2.9% month-over-month in August, compared to a revised 2.9% fall in the previous month,
Asia Pacific Markets
Asian markets closed mostly lower on Tuesday, with Japan's Nikkei 225 falling 1%, Hong Kong's Hang Seng Index dipping 9.41%, China's Shanghai Composite Index falling 4.59% and India's BSE Sensex gaining 0.72%.
The gauge for Japan's service sector fell to 47.8 in September compared to 49.0 in the prior month. Japan's current account surplus widened to JPY 3,803.6 billion in August from JPY 2,293.8 billion in the year-ago month.
Economics
<ul>
<li>The NFIB Small Business Optimism Index rose to 91.5 in September compared to 91.2 in August, and down from market estimates of 91.7.</li>
<li>The trade deficit in the U.S. shrank to $70.4 billion in August, recording the lowest level in five months, compared to a revised $78.9 billion gap in July and versus market estimates of a $70.6 billion shortfall.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41226784/how-to-earn-500-a-month-from-dominos-pizza-stock-ahead-of-q3-earnings-results"> How To Earn $500 A Month From Domino&#8217;s Pizza Stock Ahead Of Q3 Earnings Results</a></li>
</ul>
<a href="https://www.benzinga.com/news/earnings/24/10/41226784/how-to-earn-500-a-month-from-dominos-pizza-stock-ahead-of-q3-earnings-results">&nbsp;</a>

WIIM

Bio-Path shares are trading higher after the company announced it initiated a therapeutic program to develop BP1001-A for obesity and related metabolic diseases. This makes it the first application of DNAbilize technology for the development of a non-cancer application.

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 0.5% on Tuesday.
Following the market opening Tuesday, the Dow traded up 0.08% to 41,986.44 while the NASDAQ rose 0.55% to 18,022.24. The S&amp;P 500 also rose, gaining, 0.42% to 5,719.76.
Check This Out: <a href="https://www.benzinga.com/news/24/10/41224334/top-2-energy-stocks-you-may-want-to-dump-in-q4">Top 2 Energy Stocks You May Want To Dump In Q4</a>
Leading and Lagging Sectors Information technology shares jumped by 0.7% on Tuesday.
In trading on Tuesday, energy shares dipped by 2.1%.
Top Headline
PepsiCo Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>) reported mixed third-quarter results and lowered its 2024 organic revenue guidance.
The company reported a third-quarter net revenue decline of 0.6% year-over-year to $23.319 billion and organic growth of 1.3%, missing the consensus estimate of $23.825 billion. Adjusted EPS of $2.31 beat the consensus estimate of $2.29.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Alternus Clean Energy Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALCE#NASDAQ">ALCE</a>) shares shot up 76% to $0.2639. Alternus shed $100 million of debt and payables, improved shareholder equity position by Circa $45 million from disposal of certain subsidiaries.</li>
<li>Shares of Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) got a boost, surging 57% to $1.3600. The company initiated a therapeutic program to develop BP1001-A for treating obesity and related metabolic diseases. This program marks the first application of DNAbilize technology to develop a non-cancer application.</li>
<li>Nature&#8217;s Miracle Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) shares were also up, gaining 50% to $0.2037.</li>
</ul>
Equities Trading DOWN
<ul>
<li>ZJK Industrial Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJK#NASDAQ">ZJK</a>) shares dropped 29% to $4.8001 after gaining 35% on Monday.</li>
<li>Shares of OneConnect Financial Technology Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCFT#NASDAQ">OCFT</a>) were down 25% to $3.5200.</li>
<li>MMTec, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTC#NASDAQ">MTC</a>) was down, falling 24% to $0.4400.</li>
</ul>
Commodities In commodity news, oil traded down 2% to $75.60 while gold traded down 0.1% at $2,663.90.
Silver traded down 1.8% to $31.440 on Tuesday, while copper fell 1.9% to $4.4790.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.3%, Germany's DAX fell 0.1% and France's CAC 40 fell 0.5%. Spain's IBEX 35 Index rose 0.1%, while London's FTSE 100 fell 0.9%.
France's trade deficit increased to €7.4 billion in August versus a revised €6.0 billion gap in the previous month. Germany's industrial production rose by 2.9% month-over-month in August, compared to a revised 2.9% fall in the previous month,
Asia Pacific Markets
Asian markets closed mostly lower on Tuesday, with Japan's Nikkei 225 falling 1%, Hong Kong's Hang Seng Index dipping 9.41%, China's Shanghai Composite Index falling 4.59% and India's BSE Sensex gaining 0.72%.
The gauge for Japan's service sector fell to 47.8 in September compared to 49.0 in the prior month. Japan's current account surplus widened to JPY 3,803.6 billion in August from JPY 2,293.8 billion in the year-ago month.
Economics
<ul>
<li>The NFIB Small Business Optimism Index rose to 91.5 in September compared to 91.2 in August, and down from market estimates of 91.7.</li>
<li>The trade deficit in the U.S. shrank to $70.4 billion in August, recording the lowest level in five months, compared to a revised $78.9 billion gap in July and versus market estimates of a $70.6 billion shortfall.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/10/41226784/how-to-earn-500-a-month-from-dominos-pizza-stock-ahead-of-q3-earnings-results"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41226784/how-to-earn-500-a-month-from-dominos-pizza-stock-ahead-of-q3-earnings-results">How To Earn $500 A Month From Domino&#8217;s Pizza Stock Ahead Of Q3 Earnings Results</a></li>
</ul>
<a href="https://www.benzinga.com/news/earnings/24/10/41226784/how-to-earn-500-a-month-from-dominos-pizza-stock-ahead-of-q3-earnings-results">&nbsp;</a>

Bio-Path Holdings, Inc., (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) stock is trading higher on Tuesday with a strong session volume of 25.89 million compared to an average of 328.97K as per data from Benzinga Pro.
The company initiated a therapeutic program to develop BP1001-A for treating obesity and <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41224384/bio-path-holdings-initiates-development-of-therapeutic-program-for-treatment-of-obesity" rel="noreferrer noopener">related metabolic diseases</a>. This program marks the first application of DNAbilize technology to develop a non-cancer application.
The company expects to begin preclinical studies to confirm these assumptions in the fourth quarter of 2024.&nbsp;These studies are expected to provide crucial insights into the mechanism and efficacy of BP1001-A in enhancing insulin sensitivity and reveal its therapeutic potential for obesity and Type 2 diabetes.&nbsp;
The company also reported completion of enrollment in the third dosing cohort of its ongoing Phase 1/1b clinical trial evaluating BP1002 for refractory/relapsed acute myeloid leukemia (AML) patients, including venetoclax-resistant patients.
AbbVie Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>) and Roche Holdings AG&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) Genentech have partnered for Venclexta (venetoclax).
In August, Bio-Path provided an update from its ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reported continued patient progress from its ongoing Phase 2 triple combination study of prexigebersen&nbsp;in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40495366/what-happened-with-bio-path-stock-today" rel="noreferrer noopener">Acute Myeloid Leukemia</a>.
The cohort enrolled more quickly than projected, within six weeks, which underscores the ongoing need for new treatment options for these relapsed/refractory patients.
Bio-Path says that by targeting the key protein involved in the venetoclax treatment at the mRNA level, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment.
Price Action: At last check Tuesday, BPTH stock was up 51.50% at $1.30 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41227135/next-gen-nvidia-gpus-could-be-revealed-at-ces-2025-what-you-need-to-know" target="_blank" rel="noreferrer noopener">Next-Gen Nvidia GPUs Could Be Revealed at CES 2025 &#8211; What You Need to Know</a>.</li>
</ul>

Biotech

Health Care

General

ABBV

RHHBY

Nano-Cap Bio-Path Takes Plunge In Weight Loss Race, Initiates Obesity Program With Drug Candidate Under Development For Blood Cancer

<h3>Gainers</h3>
<ul>
<li>Ontrak (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTRK#NASDAQ">OTRK</a>) shares rose 63.7% to $2.98 during Tuesday's pre-market session. The company's market cap stands at $9.5 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) stock rose 51.53% to $1.29. The market value of their outstanding shares is at $3.2 million. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) stock increased by 34.8% to $0.19. The company's market cap stands at $5.1 million. </li>
<li>ZimVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) shares moved upwards by 15.35% to $17.8. The market value of their outstanding shares is at $490.7 million. </li>
<li>GRI Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRI#NASDAQ">GRI</a>) stock increased by 15.18% to $0.4. The market value of their outstanding shares is at $1.1 million. </li>
<li>Entero Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) shares rose 12.17% to $0.58. The market value of their outstanding shares is at $1.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) stock decreased by 15.5% to $0.59 during Tuesday's pre-market session. The market value of their outstanding shares is at $18.2 million. </li>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) stock fell 11.57% to $5.94. The company's market cap stands at $362.7 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) stock decreased by 10.64% to $0.12. The market value of their outstanding shares is at $1.4 million. </li>
<li>TransCode Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAZ#NASDAQ">RNAZ</a>) shares fell 9.59% to $0.49. The market value of their outstanding shares is at $8.4 million. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) shares declined by 9.24% to $0.29. The market value of their outstanding shares is at $49.4 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock fell 8.83% to $1.24. The company's market cap stands at $11.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENTO

ALPS ETF Trusthen & Steers Global Realty Majors ETF

SAGE

TRIB

TVGN

VIRI

ZIMV

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

BPTH: 74% &#x7C; <a href="https://www.benzinga.com//node/41224667">Bio-Path Has Initiated A Therapeutic Program To Develop BP1001-A For Obesity And Related Metabolic Diseases, This Program Marks The First Application Of DNAbilize Technology For Development Of A Non-cancer Application</a>
&nbsp;
DOCU: 6% &#x7C; <a href="https://www.benzinga.com//node/41225466">DocuSign shares are trading higher after it was announced the company will join the S&amp;P MidCap 400.</a>
&nbsp;
SAGE: -26% &#x7C; <a href="https://www.benzinga.com//node/41224326">Sage Therapeutics shares are trading lower after the company stops further development of dalzanemdor in Alzheimer's Disease following disappointing results from the Phase 2 LIGHTWAVE Study.</a>

Market-Moving News for October 8th

Bio-Path Has Initiated A Therapeutic Program To Develop BP1001-A For Obesity And Related Metabolic Diseases, This Program Marks The First Application Of DNAbilize Technology For Development Of A Non-cancer Application

<h3>Gainers</h3>
<ul>
<li>Theriva Biologics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TOVX#AMEX">TOVX</a>) shares moved upwards by 53.2% to $1.9 during Thursday's pre-market session. The company's market cap stands at $2.5 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares moved upwards by 22.1% to $0.12. The company's market cap stands at $11.1 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) stock moved upwards by 14.0% to $0.23. The market value of their outstanding shares is at $4.1 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) shares increased by 13.45% to $0.42. The company's market cap stands at $4.1 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares rose 12.01% to $0.99. The company's market cap stands at $2.5 million. </li>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares rose 10.69% to $8.9. The market value of their outstanding shares is at $11.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Windtree Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) stock decreased by 16.0% to $1.21 during Thursday's pre-market session. The company's market cap stands at $1.9 million. </li>
<li>Soligenix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNGX#NASDAQ">SNGX</a>) stock fell 14.79% to $4.15. The market value of their outstanding shares is at $9.4 million. </li>
<li>Kazia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KZIA#NASDAQ">KZIA</a>) shares decreased by 11.59% to $0.39. The market value of their outstanding shares is at $11.4 million. </li>
<li>ALT5 Sigma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALTS#NASDAQ">ALTS</a>) stock declined by 11.3% to $1.58. The market value of their outstanding shares is at $21.3 million. </li>
<li>Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) stock decreased by 9.63% to $4.44. The company's market cap stands at $4.6 million. </li>
<li>Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) stock decreased by 9.08% to $17.23. The company's market cap stands at $3.7 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALTS

Hims & Hers Health, Inc. Class A Common Stock

HIMS

KTTA

KZIA

NDRA

RDHL

SNGX

SYRA

TOVX

12 Health Care Stocks Moving In Thursday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) stock increased by 27.4% to $0.16 during Monday's after-market session. The company's market cap stands at $15.0 million. </li>
<li>TNF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNFA#NASDAQ">TNFA</a>) stock moved upwards by 18.82% to $2.02. The market value of their outstanding shares is at $4.7 million. </li>
<li>Holdco Nuvo Group DG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUVO#NASDAQ">NUVO</a>) stock increased by 17.64% to $0.2. The market value of their outstanding shares is at $6.6 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock rose 8.62% to $0.64. </li>
<li>Passage Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PASG#NASDAQ">PASG</a>) stock increased by 8.56% to $0.76. The market value of their outstanding shares is at $46.9 million. </li>
<li>Qilian Intl Hldg Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGM#NASDAQ">BGM</a>) stock rose 7.88% to $7.25. The market value of their outstanding shares is at $52.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) shares declined by 13.8% to $0.27 during Monday's after-market session. The market value of their outstanding shares is at $22.4 million. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock decreased by 13.46% to $0.16. The company's market cap stands at $1.0 million. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) stock fell 10.67% to $1.34. The company's market cap stands at $88.2 million. </li>
<li>Bio-Path Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) stock decreased by 8.59% to $0.91. The market value of their outstanding shares is at $2.3 million. </li>
<li>FibroBiologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBLG#NASDAQ">FBLG</a>) stock fell 8.03% to $1.49. The market value of their outstanding shares is at $52.5 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares decreased by 7.05% to $0.52. The company's market cap stands at $7.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BDRX

BJDX

FBLG

IOBT

NUVO

PASG

RNLX

TNFA

VTAK

12 Health Care Stocks Moving In Monday's After-Market Session

Bio-Path Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTH#NASDAQ">BPTH</a>) shares closed slightly higher Wednesday after the company provided an update from its ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reported continued patient progress from its ongoing Phase 2 triple combination study of prexigebersen<a href="https://www.benzinga.com/pressreleases/24/08/g40481410/bio-path-holdings-reports-solid-tumor-patient-response-supporting-bp1001-as-compelling-potential-a"> in Acute Myeloid Leukemia.</a>
The Details: Bio-Path said the first patient treated with the higher dose in its Phase 1/1b study of BP1001-A has shown tumor regression and stable disease.&nbsp;
&#8220;These positive responses mark a significant milestone for Bio-Path as they suggest our DNAbilize platform technology has the potential to produce multiple drug candidates capable of target-specific protein inhibition for over-expressed, disease-causing gene products,&#8221; said Peter H. Nielsen, CEO of Bio-Path.
Read Next: <a href="https://www.benzinga.com/news/24/08/40474316/microchip-technology-stock-dips-after-cybersecurity-incident">Microchip Technology Stock Dips After Cybersecurity Incident</a>
What Else: Bio-Path reported its second-quarter <a href="https://www.benzinga.com/pressreleases/24/08/g40390303/bio-path-holdings-reports-second-quarter-2024-financial-results">financial results </a>last week and beat analyst expectations with GAAP losses of $1.16 per share. 
Research and development expenses decreased to $1.9 million primarily due to decreased manufacturing expenses and partially offset by an increase in expenses related to its clinical trial for BP1002 in lymphoma due to increased patient enrollment in 2024.
Bio-Path shares are moving lower in Wednesday&#8217;s after-hours session. 
BPTH Stock Prediction 2024: Equity research analysts on and off Wall Street typically use earnings growth and fundamental research as a form of valuation and forecasting. But many in trading turn to technical analysis as a way to form predictive models for share price trajectory.
Some investors look to trends to help forecast where they believe a stock could trade at a certain point in the future. Looking at Bio-Path Holdings, an investor could make an assessment about a stock's long-term prospects using a moving average and trend line. 
If they believe a stock will remain above the moving average, which many believe is a bullish signal, they can extrapolate that trend into the future using a trend line. For Bio-Path, the 200-day moving average sits at $5.55, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, which is above the current price of $1.40. For more on charts and trend lines, <a href="https://pro.benzinga.com/">see a description here.</a>
Traders believe that when a stock is above its moving average, it is a generally bullish signal, and when it crosses below, it is a more negative signal. Investors could use trend lines to make an educated guess about where a stock could trade at a later date if conditions remain stable.
BPTH Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Bio-Path Holdings shares are down 6.7% after-hours at $1.40 at the time of publication Wednesday.
<ul>
<li>Read Also:<a href="https://www.benzinga.com/news/24/08/40473695/whats-going-on-with-nano-nuclear-energy-stock"> What&#8217;s Going On With Nano Nuclear Energy Stock?</a></li>
</ul>
Photo: Shutterstock

After-Hours Center

What Happened With Bio-Path Stock Today?

Bio-Path Holding shares are trading lower. The company announced an update from it's ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reports continued patient progress from the ongoing Phase 2 triple combination study of prexigebersen in Acute Myeloid Leukemia.

Bio-Path Shares Halted On Circuit Breaker To The Downside, Stock Now Down -14.2%

Bio-Path Holdings shares are trading higher after the company  provided an update from its ongoing Phase 1/1b clinical trial of BP1001-A in solid tumor patients and reported continued patient progress from the its ongoing Phase 2 triple combination study of prexigebersen in Acute Myeloid Leukemia.

Bio-Path Holdings Provides Update From Phase 1/1b Trial Of BP1001-A In Solid Tumor Patients; Says First Solid Tumor Patient Treated With Second, Higher Dose In Trial Experienced Tumor Reduction And Continued Stable Disease

Bio-Path Holdings shares are trading higher after the company reported better-than-expected Q2 EPS results.

Warning: BPTH is at high risk of performing badly

Bio-Path Q3 2024 Earnings Preview

Press Releases

Bio-Path Holdings Reports Second Quarter 2024 Financial Results

Bio-Path Holdings Reports Solid Tumor Patient Response Supporting BP1001-A's Compelling Potential as Treatment for Advanced Solid Tumors

Bio-Path Holdings to Present at H.C. Wainwright 26th Annual Global Investment Conference

Bio-Path Holdings Announces Publication in Biomedicines

Bio-Path Holdings Initiates Development of Therapeutic Program for Treatment of Obesity

ACHR, BPTH, PLUG, REGRF:

"Peraso Inc. (NASDAQ: PSRO) Pioneers mmWave Technology: The Next-Generation Wireless Communications" see bonus stocks inside…..

Financing

Bio-Path Holdings Announces $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bio-Path Holdings Announces Closing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bio-Path Holdings to Announce Third Quarter 2024 Financial Results on November 15, 2024

Comments

Bio-Path Hldgs

Bio-Path Hldgs (BPTH) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga